Cartesian Therapeutics, Inc.
NASDAQ:RNACBiotechnology
-$0.41 today
- Market cap
- $192.17M
- Beta
- 0.78
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.65
Volume 0.17M
Average 0.26M
RNAC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Cartesian Therapeutics, Inc.NASDAQ: RNAC
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $19.46M rose 32.6% year over year, ahead of the +25.5% change in trailing-twelve-month research & development. Sequentially, it rose 32.5% from the prior quarter. Over 3 fiscal years it compounded at -7.1% a year.
Context
- Research & development amounted to 2074.9% of revenue in FY2025, up 1959.0 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +32.6% holds above the trailing-twelve-month pace of +25.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 58.03M USD
- Year-over-year change
- +28.7%
- 4-year CAGR
- -4.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 58.03M | +28.7% |
| FY2024 | 2024-12-31 | 45.11M | -36.7% |
| FY2023 | 2023-12-31 | 71.26M | -1.5% |
| FY2022 | 2022-12-31 | 72.38M | +5.3% |
| FY2021 | 2021-12-31 | 68.74M | — |
Research & Development vs competitors
How RNAC compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +25.5% is the 6th highest of 9, against a peer median of +44.8%.
- Research & development amounts to 3539.3% of revenue for RNAC, versus a peer median of 184.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €83.61M EUR | -8.0% | +11.4% | 1865.0% | |
| LTM Mar 2026 | $62.82M USD | +25.5% | -7.1% | 3539.3% | |
| LTM Mar 2026 | $60.48M USD | +28.2% | +38.4% | 184.8% | |
| LTM Mar 2026 | $57.75M USD | +141.5% | +89.7% | — | |
| LTM Mar 2026 | $55.01M USD | +74.4% | +17.0% | 93235.6% | |
| LTM Mar 2026 | $40.3M USD | -12.6% | +4.1% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $27.18M USD | +72.6% | +29.4% | — |
| LTM Mar 2026 | $16.62M USD | +61.4% | +12.0% | 114.8% | |
| LTM Mar 2026 | $3.93M USD | — | — | — | |
| LTM Mar 2026 | $205K USD | -48.5% | -58.6% | 0.4% | |
| Peer median (excluding RNAC) | — | +44.8% | +14.5% | 184.8% | |
Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 85.08M | 110.78M | 26M | 38.91M | 2.8M |
| Cost of Revenue | 0 | 2.04M | 0 | 0 | 0 |
| Gross Profit | 85.08M | 108.74M | 26M | 38.91M | 2.8M |
| Gross Margin | 100.0% | 98.2% | 100.0% | 100.0% | 100.0% |
| Research & Development | 68.74M | 72.38M | 71.26M | 45.11M | 58.03M |
| Selling, General & Admin | 20.94M | 23.86M | 40.45M | 30.13M | 31.47M |
| Operating Expenses | 89.67M | 94.2M | 112.42M | 82.81M | 89.5M |
| Depreciation & Amortization | 1.72M | 2.04M | 843K | 1.15M | 2.96M |
| EBITDA | (5.16M) | 39.84M | (235.03M) | (75.99M) | (136.54M) |
| EBITDA Margin | -6.1% | 36.0% | -903.8% | -195.3% | -4881.5% |
| Operating Income | (4.6M) | 14.54M | (86.42M) | (43.9M) | (86.71M) |
| Operating Margin | -5.4% | 13.1% | -332.3% | -112.8% | -3099.9% |
| Interest Income | 0 | 0 | 4.96M | 7.39M | 6.58M |
| Interest Expense | 2.84M | 3.03M | 2.83M | 0 | 0 |
| Other Income / Expenses | (5.12M) | 20.23M | (152.29M) | (33.24M) | (52.79M) |
| Income Before Tax | (9.72M) | 34.77M | (238.71M) | (77.14M) | (139.5M) |
| Pre-Tax Margin | -11.4% | 31.4% | -918.0% | -198.2% | -4987.3% |
| Income Tax Expense | 15.97M | (609K) | (19M) | 287K | (9.19M) |
| Net Income | (25.69M) | 35.38M | (219.71M) | (77.42M) | (130.3M) |
| Net Margin | -30.2% | 31.9% | -844.9% | -199.0% | -4658.6% |
| EPS (Basic) | (6.74) | 7.33 | (49.76) | (2.99) | (5.02) |
| EPS (Diluted) | (6.60) | 3.00 | (49.76) | (3.29) | (5.02) |
| Weighted Avg Shares | 3.18M | 4.02M | 5.17M | 25.91M | 25.97M |
| Weighted Avg Shares (Diluted) | 3.18M | 4.05M | 5.17M | 23.69M | 25.97M |
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
Intrinsic Alpha fair value
Locked
Current Price
$6.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.